Skip to main content
    N

    Nektar Therapeutics (NKTR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $36.44
    -0.83 (-2.23%)

    Market Cap: $1.27B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nektar Therapeutics (NKTR) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Nektar Therapeutics (NKTR) to earn -$8.08 per share in the fiscal year ending Dec 31, 2026, on revenue of $41.82M. Of 15 analysts, 11 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 2.20, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 73% of the ratings.

    RatingAnalystsShare
    Strong Buy16.7%
    Buy1066.7%
    Hold426.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    15

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 27.7%.

    Fiscal year ending Dec 31, 2026
    -$8.08
    EPS consensus, revenue $41.82M
    Fiscal year ending Dec 31, 2027
    -$10.50
    EPS consensus, revenue $53.42M
    Next report
    Mar 10, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$8.08-$9.63 to -$6.8915$41.82M$40.00M to $45.00M15
    Dec 31, 2027-$10.50-$20.03 to -$4.1015$53.42M$8.10M to $290.78M15

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.53-$3.43 to -$1.7917$9.40M$7.45M to $12.60M17

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 4 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202620
    Fiscal year ending Dec 31, 202720

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$9.01.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$8.08-$8.08-$8.09-$8.18-$9.01N/A
    Fiscal year ending Dec 31, 2027-$10.50-$10.50-$10.25-$10.54-$10.85N/A

    Frequently Asked Questions About NKTR

    What is the NKTR stock forecast?

    Consensus analyst estimates put Nektar Therapeutics's EPS at -$8.08 for the fiscal year ending Dec 31, 2026, on revenue of $41.82M. The consensus rating from 15 analysts is Buy.

    How do analysts rate NKTR stock?

    Of 15 analysts covering Nektar Therapeutics, 1 rates it Strong Buy, 10 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from NKTR next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$8.08, with estimates from -$9.63 to -$6.89 from 15 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$10.50, with estimates from -$20.03 to -$4.10 from 15 analysts.

    What revenue do analysts expect from Nektar Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $41.82M, with estimates from $40.00M to $45.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $53.42M, with estimates from $8.10M to $290.78M.

    How many analysts cover NKTR?

    15 analysts rate Nektar Therapeutics stock, and 15 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.